

Global Osteogenesis Imperfecta Treatment Market Set For 4.4% Growth, Reaching \$1.11 Billion By 2029

*The Business Research Company's
Osteogenesis Imperfecta Treatment
Global Market Report 2025 - Market Size,
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, July 3, 2025

/EINPresswire.com/ -- Save 30% On All
Global Market Reports With Code

ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.



The Business
Research Company

The Business Research Company

How Big Is The Global Osteogenesis Imperfecta Treatment Market Expected To Grow?

[The osteogenesis imperfecta treatment global market](#) adopts a growth trajectory, escalating from \$0.89 billion in 2024 to \$0.93 billion in 2025. The market's steady progression owes its success to factors such as enhanced clinical trials for oi-specific drugs, rising investments in rare disease management, a tendency towards personalized and regenerative medicine, availability of genetic counseling, and collaborations between key industry players.

“

Save 30% On All Global
Market Reports With Code
ONLINE30 – Stay Informed
On Tariff Changes,
Macroeconomic Trends, And
More.

”

*The Business Research
Company*

Where Is The Osteogenesis Imperfecta Treatment Market
Headed?

Poised for steady growth, [the osteogenesis imperfecta treatment market size](#) is envisaged to reach a worth of

\$1.11 billion by 2029. The compound annual growth rate of 4.4% projected for the forecast period is attributable to factors such as the rising prevalence of osteogenesis imperfecta, heightened awareness and diagnostic rates of rare genetic disorders, increasing demand for effective bone health therapies, rising research funding for rare disease treatments, and developing monoclonal antibody therapies.

Get Your Free Sample Market Report:

What's Driving The Osteogenesis Imperfecta Treatment Market Growth?

A key driver for the market is the growing prevalence of osteogenesis imperfecta. This is a genetic disorder characterized by fragile bones that break easily due to defective or insufficient type I collagen. Improved genetic testing and diagnostic awareness have led to enhanced detection of previously overlooked cases. Treatments for osteogenesis imperfecta help to strengthen bones, manage symptoms, and improve quality of life. The Parliament of the United Kingdom reported in June 2022 that approximately 5,000 people in the UK are affected by osteogenesis imperfecta, further evidenced by this trend.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/osteogenesis-imperfecta-treatment-global-market-report>

Which Leading Companies Are Driving The Growth Of The Osteogenesis Imperfecta Treatment Market Share?

Prominent companies operating in the osteogenesis imperfecta treatment market include Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, BioSenic SA.

What Are The Emerging Trends In The Osteogenesis Imperfecta Treatment Market?

A noteworthy emerging trend is the inclination of major companies towards the development of advanced therapeutics, such as sclerostin inhibition therapy, to promote bone formation and lower fracture risk in osteogenesis imperfecta patients. A highlight of this trajectory is Ultragenyx Pharmaceutical Inc.'s receipt of Breakthrough Therapy Designation from the FDA in October 2024 for its investigational therapy setrusumab.

How Is The Osteogenesis Imperfecta Treatment Market Segmented?

The osteogenesis imperfecta treatment market is segmented into:

- 1 Treatment Type: Medication, Surgery, Physical Therapy, Lifestyle Modifications
- 2 Drug Class: Teriparatide, Denosumab, Other Drug Classes
- 3 Route Of Administration: Subcutaneous, Intravenous, Oral, Other Routes Of Administration
- 4 Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,
- 5 End-User: Hospitals, Homecare, Specialty Clinics, Other End Users

Insights into the various Subsegments :

- 1 Medication: Bisphosphonates, Teriparatide, Hormone Replacement Therapy, Pain Relievers, Calcium And Vitamin D Supplements

- 2 Surgery: Rodding Surgery, Spinal Fusion Surgery, Fracture Repair Surgery, Joint Replacement Surgery
- 3 Physical Therapy: Strength Training, Range Of Motion Exercises, Aquatic Therapy, Gait Training, Assistive Device Training
- 4 Lifestyle Modifications: Nutritional Counseling, Fall Prevention Strategies, Home Environment Modification, Activity Modification, Patient Education And Support Programs

What Are The Regional Insights Into The Osteogenesis Imperfecta Treatment Market?

The osteogenesis imperfecta treatment market recorded the highest performance in North America in 2024, with Asia-Pacific anticipated to exhibit the fastest growth in the forecast period. The market report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Bone Void Fillers Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/bone-void-fillers-global-market-report>

Mineral And Bone Disorder Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report>

Osteoporosis Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report>

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/828018194>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.